BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Chemistry - Pharmacology - Biochemistry

Identification of PPARgamma Partial Agonists of Natural Origin (I): Development of a Virtual Screening Procedure and In Vitro Validation
Published: Friday, November 30, 2012
Author: Laura Guasch et al.

by Laura Guasch, Esther Sala, Anna Castell-Auví, Lidia Cedó, Klaus R. Liedl, Gerhard Wolber, Markus Muehlbacher, Miquel Mulero, Montserrat Pinent, Anna Ardévol, Cristina Valls, Gerard Pujadas, Santiago Garcia-Vallvé

Background

Although there are successful examples of the discovery of new PPAR? agonists, it has recently been of great interest to identify new PPAR? partial agonists that do not present the adverse side effects caused by PPAR? full agonists. Consequently, the goal of this work was to design, apply and validate a virtual screening workflow to identify novel PPAR? partial agonists among natural products.

Methodology/Principal Findings

We have developed a virtual screening procedure based on structure-based pharmacophore construction, protein-ligand docking and electrostatic/shape similarity to discover novel scaffolds of PPAR? partial agonists. From an initial set of 89,165 natural products and natural product derivatives, 135 compounds were identified as potential PPAR? partial agonists with good ADME properties. Ten compounds that represent ten new chemical scaffolds for PPAR? partial agonists were selected for in vitro biological testing, but two of them were not assayed due to solubility problems. Five out of the remaining eight compounds were confirmed as PPAR? partial agonists: they bind to PPAR?, do not or only moderately stimulate the transactivation activity of PPAR?, do not induce adipogenesis of preadipocyte cells and stimulate the insulin-induced glucose uptake of adipocytes.

Conclusions/Significance

We have demonstrated that our virtual screening protocol was successful in identifying novel scaffolds for PPAR? partial agonists.

  More...